Upexi (UPXI) Competitors $7.05 -0.65 (-8.44%) Closing price 04:00 PM EasternExtended Trading$7.02 -0.02 (-0.35%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. TRML, CVAC, LENZ, CALT, ELVN, MAZE, DNTH, PRAX, NUVB, and COLLShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Tourmaline Bio (TRML), CureVac (CVAC), LENZ Therapeutics (LENZ), Calliditas Therapeutics AB (publ) (CALT), Enliven Therapeutics (ELVN), Maze Therapeutics (MAZE), Dianthus Therapeutics (DNTH), Praxis Precision Medicines (PRAX), Nuvation Bio (NUVB), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Tourmaline Bio CureVac LENZ Therapeutics Calliditas Therapeutics AB (publ) Enliven Therapeutics Maze Therapeutics Dianthus Therapeutics Praxis Precision Medicines Nuvation Bio Collegium Pharmaceutical Tourmaline Bio (NASDAQ:TRML) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment. Is TRML or UPXI more profitable? Tourmaline Bio has a net margin of 0.00% compared to Upexi's net margin of -86.54%. Tourmaline Bio's return on equity of -30.50% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -30.50% -29.63% Upexi -86.54%-54.33%-31.28% Does the media favor TRML or UPXI? In the previous week, Upexi had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 5 mentions for Upexi and 4 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.70 beat Upexi's score of 0.62 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TRML or UPXI? Tourmaline Bio has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Which has preferable earnings and valuation, TRML or UPXI? Upexi has higher revenue and earnings than Tourmaline Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$73.21M-$3.43-13.96Upexi$15.81M26.26-$13.68MN/AN/A Do institutionals and insiders have more ownership in TRML or UPXI? 91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 4.4% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TRML or UPXI? Tourmaline Bio presently has a consensus target price of $45.65, indicating a potential downside of 4.68%. Upexi has a consensus target price of $15.50, indicating a potential upside of 119.86%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryTourmaline Bio beats Upexi on 7 of the 13 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$453.44M$3.15B$35.82B$10.65BDividend YieldN/A1.61%2.84%4.73%P/E RatioN/A12.1521.5222.85Price / Sales26.2659.26766.23135.18Price / CashN/A52.9730.0561.77Price / Book6.988.088.326.70Net Income-$13.68M$27.08M$196.75M$276.44M7 Day Performance22.18%6.02%2.58%3.13%1 Month Performance16.72%22.10%13.72%10.21%1 Year Performance171.15%101.49%84.13%40.35% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi2.4871 of 5 stars$7.05-8.4%$15.50+119.9%+229.1%$453.44M$15.81M0.00130Short Interest ↑Gap UpTRMLTourmaline Bio1.7007 of 5 stars$48.16+0.9%$45.65-5.2%+79.1%$1.23BN/A-14.0444Short Interest ↓CVACCureVac3.999 of 5 stars$5.35-0.4%$6.83+27.7%+79.1%$1.20B$579.18M5.57880LENZLENZ Therapeutics0.6965 of 5 stars$44.89+6.8%$49.60+10.5%+78.9%$1.20B$5M-23.63110CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ELVNEnliven Therapeutics2.5321 of 5 stars$20.30+1.4%$41.20+103.0%-26.3%$1.19BN/A-10.1550MAZEMaze Therapeutics3.9587 of 5 stars$25.20-6.7%$33.83+34.3%N/A$1.18B$167.50M0.00121DNTHDianthus Therapeutics2.9802 of 5 stars$39.55+7.7%$61.57+55.7%+23.1%$1.18B$6.24M-12.1780PRAXPraxis Precision Medicines2.2358 of 5 stars$52.38-0.1%$85.56+63.3%-21.5%$1.10B$8.55M-4.26110NUVBNuvation Bio2.902 of 5 stars$3.22+0.6%$7.86+144.0%+56.4%$1.10B$7.87M-5.1160COLLCollegium Pharmaceutical4.1454 of 5 stars$34.57+0.5%$42.33+22.5%-19.2%$1.08B$631.45M33.24210Positive News Related Companies and Tools Related Companies TRML Alternatives CVAC Alternatives LENZ Alternatives CALT Alternatives ELVN Alternatives MAZE Alternatives DNTH Alternatives PRAX Alternatives NUVB Alternatives COLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
